Section one: Contracting authority
one.1) Name and addresses
NHS England
Quarry House, Quarry Hill
Leeds
LS2 7UE
Contact
NHSE Commercial Team
england.cancervaccinelaunchpad@nhs.net
Country
United Kingdom
Region code
UK - United Kingdom
Internet address(es)
Main address
Buyer's address
one.3) Communication
Additional information can be obtained from the above-mentioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at
https://health-family.force.com/s/Welcome
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Cancer Vaccine Launchpad (CVLP)
two.1.2) Main CPV code
- 85100000 - Health services
two.1.3) Type of contract
Services
two.1.4) Short description
You are invited to attend a virtual market engagement for the Cancer Vaccine Launch Pad (CVLP).
Overview
The CVLP is a strategic priority and collaboration between NHS England, the Department of Health and Social Care (DHSC), the Office for Life Sciences (OLS), the National Institute of Health Research (NIHR) and Genomics England (GEL), with the aim to facilitate access to personalised cancer vaccine research trials. The project was jointly announced in July 2023 with the Secretary of State and in partnership with the Prime Minister. See link (https://www.gov.uk/government/news/major-agreement-to-deliver-new-cancer-vaccine-trials#:~:text=It%20will%20work%20by%20creating,become%20part%20of%20standard%20care)
Through the CVLP platform, cancer patients from across a network of up to 140 NHS cancer care providers will be asked to consent to be put forward for clinical trials. Their surplus tissue samples, obtained through standard of care pathways, will be used to assess their eligibility. The detail of any available trials will be shared with the participant and their treating clinical team to see if the patient wishes to take part, and if so, the patient will travel to the nearest trial site to access the clinical trial.
The CVLP is company agnostic and is being set up in a phased approach with a small number of Trusts to test the pathway from September 2023. For the first phase, the CVLP is supporting one cancer vaccine clinical trial. It is likely that three to four additional trials will be brought into the CVLP during 2024.
NHS England is looking for a supplier to provide the digital infrastructure and clinical liaison function to manage the end-to-end pathway of the CVLP for up to 2000 patients until March 2025.
Estimated spend (excl. VAT): £1,400,000
Estimated Duration: 15 months
Contract duration:
Proposed contract start date: 01/01/2024
Proposed contract end date: 31/03/2025
Date of event: October 17th, 2023, 9.30am – 11:00am
Attendees are limited to 2 per company. To register your interest please contact england.cancervaccinelaunchpad@nhs.net and state the names and titles of those intending to attend.
Thank you.
two.1.5) Estimated total value
Value excluding VAT: £1,400,000
two.1.6) Information about lots
This contract is divided into lots: No
two.2) Description
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
PIN notice only for market engagement. Details contained in the short description
two.2.14) Additional information
N/A
two.3) Estimated date of publication of contract notice
20 October 2023
Section four. Procedure
four.1) Description
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: No